Preclinical efficacy study results for the first Russian humanised monoclonal antibody OM-RCA-01, indicated for treatment of renal cell carcinoma, were presented at the New Technologies session of the Congress of the American Society of Clinical Oncology (ASCO...
The second annual awarding ceremony of Investor Awards 2012 winners took place on May 23 in Moscow after the end of the forum Invest in Russia. The investment round in the innovative biotechnological company OncoMax, that received investments from Maxwell Biotech...
OncoMax presented its research results at the 5 th European Multidisciplinary Meeting on Urological Cancers (EMUC) which was held in Marseille, France on 15-17 November 2013. Dr. Ilya Tsimafeyev, Scientific Advisor of Oncomax, won the First Prize for...
From 13 to 15 November 2012, the World Trade Center, Moscow, will host the XVI Russian Cancer Congress featuring expositions of the largest pharmaceutical and biotechnology companies in the Russian cancer market. The event will be attended by Skolkovo Biomedical...
Biotechnological company OncoMax, Ltd has increased the commercial value of its patent portfolio due to the U.S. patent (US 8487083 July 16, 2013). The document proves originality and innovation of the developed medicine OM-RCA-01, a monoclonal antibody specific...
OncoMax, Ltd. (“OncoMax”), a portfolio company of Russia-based Maxwell Biotech Venture Fund founded with the participation of Russian Venture Company announced today that it will be presenting the results of development of its lead product OM-RCA-01 at 4 major...
OncoMax presented the results of its research in the field of onco-urologic diseases at the 27 th Annual Congress of the European Association of Urologists taking place in Paris during February 24-28. Based on the research results measuring the effectiveness...